Article
Asthma in adults and adolescents: redefining the role of short-acting beta-2 agonists
- Aust Prescr 2026;49:212-7
- 1 December 2026
- DOI: 10.18773/austprescr.2026.048


Recent updates to the Australian Asthma Handbook represent a major shift in asthma management for adults and adolescents. The most important change is the move away from short-acting beta2 agonist (SABA)–only treatment (as-needed salbutamol or terbutaline) for mild intermittent asthma, because SABA monotherapy does not address underlying airway inflammation and is associated with an increased risk of severe exacerbations and asthma-related death.
Inhaled corticosteroid–containing therapies are now recommended for all adults and adolescents with asthma of any severity, for their anti-inflammatory effects.
The preferred treatment for mild asthma is as-needed anti-inflammatory reliever (AIR) therapy, comprising low-dose budesonide plus formoterol in a single inhaler, taken only when symptoms occur.
For patients with moderate or severe asthma, the preferred treatment is maintenance-and-reliever therapy (MART), which is budesonide plus formoterol, or beclometasone plus formoterol, in a single inhaler, used regularly and as needed.
The recommended role for SABA inhalers is now limited to the management of acute asthma and exercise-induced bronchoconstriction, as well as reliever therapy for patients using traditional (non-MART) maintenance regimens.
The updated recommendations emphasise preventing exacerbations and reducing the overuse of SABA relievers through the early introduction of anti-inflammatory treatment. Referral to a respiratory physician is recommended when there is diagnostic uncertainty, frequent exacerbations or poor symptom control despite optimised therapy, or for consideration of treatment with biologics.
Asthma affects approximately 1 in 9 Australians.1 Despite the availability of effective therapies, preventable exacerbations, hospitalisations and deaths continue to occur and there are opportunities for better care.2
Historically, asthma management in people with mild or infrequent symptoms relied heavily on short-acting beta2 agonist (SABA) monotherapy (salbutamol or terbutaline) for rapid symptom relief.3 This approach reinforced the perception among patients that asthma was primarily a disease of bronchoconstriction rather than chronic airway inflammation. Studies have demonstrated that SABA overuse is associated with increased exacerbation risk, hospitalisation and mortality.4,5
The 2025 update of the Australian Asthma Handbook introduces substantial changes in the management of adults and adolescents (age 12 years and over).6 The revised recommendations emphasise anti-inflammatory treatment (inhaled corticosteroid; ICS) from diagnosis onwards and discourage SABA–only therapy, even for mild asthma. Combination inhalers containing an anti-inflammatory (budesonide or beclometasone) plus a non–SABA reliever (formoterol, a quick-onset long-acting beta2 agonist) are now the recommended treatment for all patients. These changes represent one of the most significant shifts in asthma management in decades.
This article summarises the redefined role of SABAs and preferred asthma management approaches in adults and adolescents. The management of asthma in children is addressed in another article in this issue of the journal.7
The overall goals of asthma management are to achieve good symptom control, prevent exacerbations, preserve lung function and minimise the adverse effects of treatment. Contemporary management also emphasises patient-centred care, optimising inhaler technique, self-management education and regular review.
A key principle underpinning the updated guidelines is that all adults and adolescents with asthma should be prescribed anti-inflammatory treatment (an ICS), even when symptoms are mild or intermittent, and SABA–only use should be avoided. This recommendation recognises that airway inflammation is present even in mild asthma and that symptom frequency alone does not reliably predict exacerbation risk.
SABAs have an important role in acute asthma management (see below); however, as-needed SABA treatment is no longer recommended for ongoing management because it does not treat airway inflammation, may reinforce overreliance on bronchodilator therapy and is associated with higher exacerbation risk, hospitalisation and mortality.4
Many patients who experience severe exacerbations report infrequent day-to-day symptoms but rely heavily on SABA inhalers.3 Regular or excessive SABA use may increase airway hyperresponsiveness and delay escalation of anti-inflammatory treatment.8 In contrast, the early introduction of anti-inflammatory ICS therapy improves lung function and reduces exacerbations.9
Instead of using an as-needed SABA inhaler, the recommended initial treatment for mild asthma is now anti-inflammatory reliever (AIR)–only therapy, comprising low-dose budesonide plus formoterol in a single inhaler, taken as-needed for symptom relief (Figure 1, treatment level 1).6,10 As-needed AIR–only therapy combines rapid bronchodilation from formoterol, a quick-onset, long-acting beta2 agonist (LABA), with immediate delivery of budesonide (an ICS). Approved inhalers for AIR therapy are detailed in Table 1.
The figure illustrates the 4 treatment levels for adults and adolescents with asthma. Treatment should be stepped up or down based on severity and frequency of asthma symptoms. Level 1 is AIR-only therapy with low-dose budesonide+formoterol used only when required. Levels 2 and 3 are ICS+formoterol used regularly and as-needed (known as MART); level 2 uses low-dose ICS while level 3 uses medium-dose ICS. Level 4 is targeted intensive treatment and specialist review. Consider stepping up if good symptom control is not achieved despite good adherence and correct inhaler technique. Consider stepping down when asthma is stable and well controlled for 2 to 3 months.
Patients should carry their AIR inhaler at all times and use it whenever they experience difficulty breathing, or before anticipated exposure to triggers (e.g. exercise or allergen exposure).6 If needed, the patient can take more doses to relieve the symptoms, up to a maximum of 72 micrograms per day of formoterol (12 doses of the 6 microgram inhaler strength or 24 doses of the 3 microgram inhaler strength). In practice, the daily maximum dose is rarely needed, but the use of such doses signals a need for medical review.6
The rationale for AIR–only therapy is clinically compelling. Patients with mild asthma often have poor adherence to regular preventer therapy because symptoms are intermittent.12 By linking anti-inflammatory treatment to symptom-driven inhaler use, AIR therapy delivers corticosteroid treatment at times of increased airway inflammation and worsening symptoms.
Randomised trials have shown that AIR–only therapy (as-needed budesonide plus formoterol) substantially reduces severe exacerbations compared with SABA–only treatment while exposing patients to a lower cumulative ICS dose than daily maintenance ICS in some populations.13-16
For patients with more frequent or severe symptoms, or high exacerbation risk, MART is the recommended starting treatment approach (Figure 1, treatment levels 2 and 3).6,11 MART uses a single inhaler that contains an ICS plus the quick-onset LABA formoterol as both maintenance (regular everyday dosing) and reliever (as-needed) therapy. Not all ICS+formoterol inhalers are approved for MART; for approved combinations and strengths, see Table 1.
MART simplifies treatment regimens and reduces reliance on SABAs. Importantly, it allows patients to self-titrate anti-inflammatory treatment in response to worsening symptoms by taking additional doses of ICS+formoterol when needed. Clinical trials have consistently shown that MART reduces severe exacerbations compared with traditional fixed-dose ICS+LABA therapy used with as-needed SABA reliever.17
MART is particularly valuable in patients with a history of exacerbations or poor adherence to preventer inhalers. It also reduces confusion associated with multiple inhalers and reinforces the concept that symptom relief and anti-inflammatory treatment should occur together.
Table 1 Inhaled medications approved for anti-inflammatory reliever (AIR) therapy or maintenance-and-reliever therapy (MART) use in adults and adolescents
| Medication combinations | Strength (micrograms) | Inhaler device type (device brand names) [NB1] | AIR–only dose [NB2] | MART dose [NB3] | Maximum dose [NB4] |
|
budesonide+formoterol |
200+6 [NB5] |
Dry powder inhaler (Turbuhaler, Easyhaler or Spiromax) |
1 inhalation as needed for symptom relief |
1 or 2 inhalations twice daily (maintenance), plus 1 inhalation as needed (symptom relief) Spiromax inhaler approved only for adults (age 18 years and over) |
6 inhalations per occasion 12 inhalations in one day temporarily |
|
budesonide+formoterol |
100+3 |
pMDI |
2 inhalations as needed for symptom relief |
2 to 4 inhalations twice daily (maintenance), plus 2 inhalations as needed (symptom relief) |
12 inhalations per occasion 24 inhalations in one day temporarily |
|
beclometasone+formoterol |
100+6 |
pMDI |
Not approved |
1 inhalation twice daily (maintenance), plus 1 inhalation as needed (symptom relief) Approved only for adults (age 18 years and over) |
6 inhalations per occasion 8 inhalations per day |
| AIR = anti-inflammatory reliever; MART = maintenance-and-reliever therapy; pMDI = pressurised metered dose inhaler NB1: Guidance on inhaler device selection is available: Inhaler device selection for people with asthma or chronic obstructive pulmonary disease. NB2: AIR–only therapy comprises anti-inflammatory+reliever therapy (corticosteroid+quick-onset, long-acting beta2 agonist) in a single inhaler used only as needed for mild or intermittent asthma. NB3: MART comprises maintenance+reliever therapy (corticosteroid+quick-onset, long-acting beta2 agonist) in a single inhaler used regularly and as needed. NB4: Maximum doses as stated in approved product information. Daily maximum doses are rarely needed in practice.6 NB5: Budesonide+formoterol 100/6 micrograms dry powder inhaler is also approved for MART; however, the 200/6 micrograms strength has a stronger evidence base and is preferred. | |||||
Although ICS+formoterol–based regimens (AIR and MART) are preferred, daily maintenance ICS or ICS+LABA with a SABA reliever may still be appropriate in some circumstances, such as when patients are stable on existing therapy or have difficulty understanding AIR or MART regimens.6
Asthma management should be reviewed regularly, particularly after exacerbations or treatment changes. Assessment and education should include symptom control, exacerbation history, reliever use, comorbidities, inhaler technique, adherence, recognition of worsening asthma, trigger management and a written asthma action plan. Some patients may benefit from a multidisciplinary approach, including asthma educators or pharmacists (e.g. via Home Medicines Review).
Excessive reliever use is an important marker of poor control. The dispensing of 3 or more SABA canisters annually is associated with increased exacerbation risk and should prompt clinical review.18
Regardless of reliever type (including AIR and MART regimens), poor asthma control despite good adherence and inhaler technique should prompt a change in therapy.
Poor asthma control despite MART therapy with medium-dose ICS presents a challenge for clinicians. A traditional option was to prescribe a high-dose ICS, but the efficacy of this is doubtful.19 Another more recent option is ‘triple therapy’, which is a long-acting muscarinic antagonist (LAMA) with an ICS and a LABA. Although heavily promoted and available on the Australian Pharmaceutical Benefits Scheme (PBS), triple therapy makes little difference to asthma control and prevents asthma exacerbations only modestly compared with biologic therapies.20 Triple therapy has a limited role in patients with severe asthma who do not qualify for therapy with biologics. The introduction of triple therapy should not delay referral for consideration of biologic therapies.
Biologic therapies have transformed the management of severe asthma with persistent type 2 inflammation.21 They target specific inflammatory pathways, including IgE, thymic stromal lymphopoietin or interleukins 4, 5 or 13.
Biologics should be considered only after confirming the diagnosis of asthma and addressing modifiable contributors to poor control.22 Many patients labelled as having severe asthma actually have difficult-to-treat asthma related to poor adherence, incorrect inhaler technique, comorbidities (e.g. smoking, obesity, dysfunctional breathing, allergic rhinitis, gastro-oesophageal reflux disease) or psychosocial factors.23
Patients who may benefit from biologic therapy typically have:22
The selection of biologic therapy is made by physicians such as respiratory physicians, immunologists or allergists. The choice of biologic therapy depends on clinical phenotype, biomarker profile, exacerbation history and eligibility criteria under the PBS.
Biologics can substantially reduce exacerbations, oral corticosteroid exposure and healthcare utilisation.21 They may also improve quality of life and lung function.21 Biologic therapies require specialist assessment and ongoing review to evaluate treatment response and continued need.
Referral to a respiratory physician should be considered when the diagnosis is uncertain, asthma remains poorly controlled despite guideline-based treatment, or severe asthma is suspected.
Specific indications for referral include:
Respiratory specialist assessment may include spirometry, fractional exhaled nitric oxide (FeNO), bronchial provocation testing, biomarker assessment, allergy testing and evaluation for alternative diagnoses or comorbidities.
SABAs are effective rapid-onset bronchodilators and are still recommended for acute asthma management, exercise-induced bronchoconstriction, and reliever therapy for some patients using traditional maintenance regimens. Vigilance regarding maintenance ICS adherence is vital when traditional regimens are used, and excessive SABA use (3 or more inhalers supplied in 12 months) should prompt clinical review.4
For exercise-induced bronchoconstriction, inhaled salbutamol is effective when used as needed for symptoms or when taken 5 to 15 minutes before exercise to prevent short-term symptoms. It may be particularly useful for patients with infrequent exercise-related symptoms.24 However, frequent exercise-induced symptoms should prompt reassessment of overall asthma control and consideration of regular ICS–containing therapy.24 For patients with asthma, budesonide+formoterol in a single inhaler taken as needed seems more effective than SABA alone for exercise-induced asthma.25
For acute asthma management, inhaled salbutamol, administered via a pressurised metered dose inhaler and spacer or via a nebuliser, is recommended for rapid bronchodilation during acute exacerbations in primary care and emergency settings.
In some patients, particularly those with longstanding reliance on salbutamol, transitioning away from SABA–dominant management may be challenging.26 The availability of SABAs without prescription in Australia likely contributes to the underuse of ICS therapies.5,27 Many patients perceive SABAs as highly effective because of their immediate symptomatic benefit and may therefore undervalue preventer therapy.28 Consequently, patient education and shared decision-making are critical when implementing AIR–only or MART approaches.26
Updates to the Australian Asthma Handbook have fundamentally changed asthma management in adults and adolescents, with a shift towards the universal use of combination inhalers containing an ICS plus formoterol (AIR or MART), reflecting evidence that these treatments reduce severe exacerbations and improve outcomes. SABAs have a role in select situations (e.g. acute asthma), but excessive use is associated with increased risk and should prompt clinical review. Biologic therapies offer an important treatment option for select patients with severe asthma.
- For patients with mild intermittent asthma, start treatment with anti-inflammatory reliever (AIR)–only therapy (low-dose budesonide plus formoterol in a single inhaler, taken as needed when symptoms occur).
- For patients requiring maintenance treatment, prescribe maintenance-and-reliever therapy (MART), which is low- to moderate-dose budesonide plus formoterol or beclometasone plus formoterol in a single inhaler, used both regularly and as needed. MART reduces severe exacerbations and is preferred over fixed-dose ICS regimens.
This article was finalised on 21 September 2026.
Conflicts of interest: Debbie Rigby is the Clinical Executive Lead for the National Asthma Council. Debbie has received honoraria from AstraZeneca, Boehringer Ingelheim, Care Pharmaceuticals, Chiesi, GSK, Menarini, Moderna, MSD, Respiri, Teva and Viatris for presentations, conferences, travel or advisory board roles.
Brett Montgomery is the chair of the National Asthma Council’s Guidelines Committee.
This article is peer reviewed.
Australian Prescriber welcomes Feedback.
Advanced Practice Pharmacist and Asthma Educator, DR Pharmacy Consulting, Brisbane
Clinical Executive Lead, National Asthma Council Australia
Adjunct Associate Professor, School of Pharmacy, The University of Queensland, Brisbane
Clinical Associate Professor, Discipline of Pharmacy, Queensland University of Technology, Brisbane
Senior Lecturer, Department of General Practice, Medical School, University of Western Australia, Perth
General Practitioner, East Fremantle Medical Centre, Perth